RB1 and cancer: The disruption and hyperactivation of the Cdk4-cyclin D/pRb/E2F pathway in most cancer types such as malignant sarcomas, gliomas, and breast carcinomas [1, 10–12] have made the Cdk4-cyclin D complex an attractive molecular target for cancer therapy [13].